Naar www.iknl.nl
- Primaire tumor onbekend > Primaire tumor onbekend
Notificatie richtlijn E-mail richtlijn Naar startpagina oncoline
----------

Laatst gewijzigd : 2012-06-24, Versie: 1.0, Verantwoording: Nederlandse Vereniging voor Pathologie, Type: Landelijke richtlijn

Referentielijst

1 - NICE (2010)
NICE. NIfHaCE. Diagnosis and management of metastatic malignant disease of unknown primary origin. Evidence review. 2010 [cited; Available from: http://www.nice.org.uk/nicemedia/live/13044/49897/49897.pdf
 
2 - NICE (2010)
NICE. NIfHaCE. Diagnosis and management of metastatic malignant disease of unknown primary origin. Full Guideline. 2010 [cited; Available from: http://www.nice.org.uk/nicemedia/live/13044/49864/49864.pdf
 
3 - NKR (2010)
NKR. NK. Nederlandse Kankerregristratie. Sterftecijfers. 2010.
 
4 - Adenis A (2010)
Adenis A, Ferte C, Penel N. Phase II trials in patients with carcinoma of unknown primary: a pooled data analysis. Invest New Drugs. 2010; 28(2): 178-84.
 
5 - Agazzi S (2004)
Agazzi S, Pampallona S, Pica A, Vernet O, Regli L, Porchet F, et al. The origin of brain metastases in patients with an undiagnosed primary tumour. Acta Neurochir (Wien). 2004; 146(2): 153-7.
 
6 - Alberini JL (2003)
Alberini JL, Belhocine T, Hustinx R, Daenen F, Rigo P. Whole-body positron emission tomography using fluorodeoxyglucose in patients with metastases of unknown primary tumours (CUP syndrome). Nucl Med Commun. 2003; 24(10): 1081-6.
 
7 - Al-Brahim N (2005)
Al-Brahim N, Ross C, Carter B, Chorneyko K. The value of postmortem examination in cases of metastasis of unknown origin-20-year retrospective data from a tertiary care center. Ann Diagn Pathol. 2005; 9(2): 77-80.
 
8 - Balaker AE A (2012)
Balaker AE A, Elashoof D, John MA. Cancer of Unknown Primary: Does Treatment Modality Make a Difference? Laryngoscope. 2012; 122: 1279-82.
 
9 - Bannas P (2010)
Bannas P, Weber C, Derlin T, Lambert J, Leypoldt F, Adam G, et al. 18F-FDG-PET/CT in the diagnosis of paraneoplastic neurological syndromes: a retrospective analysis. Eur Radiol. 2010; 20(4): 923-30.
 
10 - Barker EV (2009)
Barker EV, Cervigne NK, Reis PP, Goswami RS, Xu W, Weinreb I, et al. microRNA evaluation of unknown primary lesions in the head and neck. Mol Cancer. 2009; 8:127.
 
11 - Bartelt S (2003)
Bartelt S, Lutterbach J. Brain metastases in patients with cancer of unknown primary. J Neurooncol. 2003; 64(3): 249-53.
 
12 - Bauwens S (2009)
Bauwens S, Baillon C, Distelmans W, Theuns P. The 'Distress Barometer': validation of method of combining the Distress Thermometer with a rated complaint scale. Psychooncology. 2009; 18(5): 534-42.
 
13 - Bocking A (2009)
Bocking A, Pomjansky N, Buckstegge B, Onofre A. [Immunocytochemical identification of carcinomas of unknown primaries on fine-needle-aspiration-biopsies]. Pathologe. 2009; 30 Suppl 2: 158-60.
 
14 - Boyland L (2008)
Boyland L, Davis C. Patients' experiences of carcinoma of unknown primary site: dealing with uncertainty. Palliat Med. 2008; 22(2): 177-83.
 
15 - Cameron SE (2010)
Cameron SE, Andrade RS, Pambuccian SE. Endobronchial ultrasound-guided transbronchial needle aspiration cytology: a state of the art review. Cytopathology. 2010; 21(1): 6-26.
 
16 - Carroll MC (2002)
Carroll MC, Fleming M, Chitambar CR, Neuburg M. Diagnosis, workup, and prognosis of cutaneous metastases of unknown primary origin. Dermatol Surg. 2002; 28(6): 533-5.
 
17 - CBO KvdG (2007)
CBO KvdG. Evidence-based richtlijnontwikkeling. Handleiding voor werkgroepleden. 2007 [cited; Available from: http://www.cbo.nl/thema/Richtlijnen/EBRO-handleiding
 
18 - Chen AM (2011)
Chen AM, Farwell DG, Lau DH, Li BQ, Luu Q, Donald PJ. Radiation Therapy in the Management of Head-and-Neck Cancer of Unknown Primary Origin: How Does the Addition of Concurrent Chemotherapy Affect the Therapeutic Ratio? Int J Radiat Oncol Biol Phys. 2011; 81(2): 346-52.
 
19 - Cianchetti M (2009)
Cianchetti M, Mancuso AA, Amdur RJ, Werning JW, Kirwan J, Morris CG, et al. Diagnostic evaluation of squamous cell carcinoma metastatic to cervical lymph nodes from an unknown head and neck primary site. Laryngoscope. 2009; 119(12): 2348-54.
 
20 - Culine S (2003)
Culine S, Lortholary A, Voigt JJ, Bugat R, Theodore C, Priou F, et al. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol. 2003; 21(18): 3479-82.
 
21 - Culine S (2009)
Culine S. Prognostic factors in unknown primary cancer. Semin Oncol. 2009; 36(1): 60-4.
 
22 - D'Ambrosio AL (2007)
D'Ambrosio AL, Agazzi S. Prognosis in patients presenting with brain metastasis from an undiagnosed primary tumor. Neurosurg Focus. 2007; 22(3): E7.
 
23 - de Bresser J (2010)
de Bresser J, de Vos B, van der Ent F, Hulsewe K. Breast MRI in clinically and mammographically occult breast cancer presenting with an axillary metastasis: a systematic review. Eur J Surg Oncol. 2010; 36(2): 114-9.
 
24 - Destombe C (2007)
Destombe C, Botton E, Le Gal G, Roudaut A, Jousse-Joulin S, Devauchelle-Pensec V, et al. Investigations for bone metastasis from an unknown primary. Joint Bone Spine. 2007; 74(1): 85-9.
 
25 - Dong MJ (2008)
Dong MJ, Zhao K, Lin XT, Zhao J, Ruan LX, Liu ZF. Role of fluorodeoxyglucose-PET versus fluorodeoxyglucose-PET/computed tomography in detection of unknown primary tumor: a meta-analysis of the literature. Nucl Med Commun. 2008; 29(9): 791-802.
 
26 - Dova L (2007)
Dova L, Pentheroudakis G, Georgiou I, Malamou-Mitsi V, Vartholomatos G, Fountzilas G, et al. Global profiling of EGFR gene mutation, amplification, regulation and tissue protein expression in unknown primary carcinomas: to target or not to target? Clin Exp Metastasis. 2007; 24(2): 79-86.
 
27 - Dova L (2008)
Dova L, Pentheroudakis G, Golfinopoulos V, Malamou-Mitsi V, Georgiou I, Vartholomatos G, et al. Targeting c-KIT, PDGFR in cancer of unknown primary: a screening study for molecular markers of benefit. J Cancer Res Clin Oncol. 2008; 134(6): 697-704.
 
28 - Eickhoff A (2007)
Eickhoff A, Spiethoff A, Hartmann D, Jakobs R, Weickert U, Schilling D, et al. [Space-occupying lesions in the liver: incidence of adenocarcinoma metastases of unknown primary site]. Dtsch Med Wochenschr. 2007; 132(8): 369-74.
 
29 - Fandi A (1995)
Fandi A, Cvitkovic E. Biology and treatment of nasopharyngeal cancer. Curr Opin Oncol. 1995; 7(3): 255-63.
 
30 - Faure E (2000)
Faure E, Riquet M, Lombe-Weta PM, Hubsch JP, Carnot F. [Malignant mediastinal lymph node tumors with unknown primary cancers]. Rev Mal Respir. 2000; 17(6): 1095-9.
 
31 - Fencl P (2007)
Fencl P, Belohlavek O, Skopalova M, Jaruskova M, Kantorova I, Simonova K. Prognostic and diagnostic accuracy of [18F]FDG-PET/CT in 190 patients with carcinoma of unknown primary. Eur J Nucl Med Mol Imaging. 2007; 34(11): 1783-92.
 
32 - Ferte C (2010)
Ferte C, Penel N, Bonneterre J, Adenis A. Individual life expectancy estimation using validated prognostic scores for patients with cancer of unknown primary. Oncology. 2010; 78(2): 87-93.
 
33 - Fogarty GB (2003)
Fogarty GB, Peters LJ, Stewart J, Scott C, Rischin D, Hicks RJ. The usefulness of fluorine 18-labelled deoxyglucose positron emission tomography in the investigation of patients with cervical lymphadenopathy from an unknown primary tumor. Head Neck. 2003; 25(2): 138-45.
 
34 - Frank SJ (2010)
Frank SJ, Rosenthal DI, Petsuksiri J, Ang KK, Morrison WH, Weber RS, et al. Intensity-modulated radiotherapy for cervical node squamous cell carcinoma metastases from unknown head-and-neck primary site: M. D. Anderson Cancer Center outcomes and patterns of failure. Int J Radiat Oncol Biol Phys. 2010; 78(4): 1005-10.
 
35 - Giordana MT (2000)
Giordana MT, Cordera S, Boghi A. Cerebral metastases as first symptom of cancer: a clinico-pathologic study. J Neurooncol. 2000; 50(3): 265-73.
 
36 - Glockner JF (2000)
Glockner JF, White LM, Sundaram M, McDonald DJ. Unsuspected metastases presenting as solitary soft tissue lesions: a fourteen-year review. Skeletal Radiol. 2000; 29(5): 270-4.
 
37 - Goldenberg D (2006)
Goldenberg D, Sciubba J, Koch WM. Cystic metastasis from head and neck squamous cell cancer: a distinct disease variant? Head Neck. 2006; 28(7): 633-8.
 
38 - Golfinopoulos V (2009)
Golfinopoulos V, Pentheroudakis G, Salanti G, Nearchou AD, Ioannidis JP, Pavlidis N. Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple-treatments meta-analysis. Cancer Treat Rev. 2009; 35(7): 570-3.
 
39 - Greco FA (2000)
Greco FA, Erland JB, Morrissey LH, Burris HA, 3rd, Hermann RC, Steis R, et al. Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol. 2000; 11(2): 211-5.
 
40 - Greco FA (2009)
Greco FA, Erlander MG. Molecular classification of cancers of unknown primary site. Mol Diagn Ther. 2009; 13(6): 367-73.
 
41 - Greco FA (2009)
Greco FA, Pavlidis N. Treatment for patients with unknown primary carcinoma and unfavorable prognostic factors. Semin Oncol. 2009; 36(1): 65-74.
 
42 - Greco FA (2010)
Greco FA, Spigel DR, Yardley DA, Erlander MG, Ma XJ, Hainsworth JD. Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction. Oncologist. 2010; 15(5): 500-6.
 
43 - Guntinas-Lichius O (2006)
Guntinas-Lichius O, Peter Klussmann J, Dinh S, Dinh M, Schmidt M, Semrau R, et al. Diagnostic work-up and outcome of cervical metastases from an unknown primary. Acta Otolaryngol. 2006; 126(5): 536-44.
 
44 - Gutzeit A (2005)
Gutzeit A, Antoch G, Kuhl H, Egelhof T, Fischer M, Hauth E, et al. Unknown primary tumors: detection with dual-modality PET/CT--initial experience. Radiology. 2005; 234(1): 227-34.
 
45 - Haas I (2001)
Haas I, Hauser U, Ganzer U. The dilemma of follow-up in head and neck cancer patients. Eur Arch Otorhinolaryngol. 2001; 258(4): 177-83.
 
46 - Haas I (2002)
Haas I, Hoffmann TK, Engers R, Ganzer U. Diagnostic strategies in cervical carcinoma of an unknown primary (CUP). Eur Arch Otorhinolaryngol. 2002; 259(6): 325-33.
 
47 - Hainsworth JD (2009)
Hainsworth JD, Fizazi K. Treatment for patients with unknown primary cancer and favorable prognostic factors. Semin Oncol. 2009; 36(1): 44-51.
 
48 - Hainsworth JD (2010)
Hainsworth JD, Spigel DR, Clark BL, Shipley D, Thompson DS, Farley C, et al. Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial. Cancer J. 2010; 16(1): 70-5.
 
49 - Hamers JP (2010)
Hamers JP, Hibbard J, Visser A. Editorial. Changing patient education. Patient Educ Couns. 2010; 78(3): 273-4.
 
50 - Han CM (2008)
Han CM, Lee CL, Huang KG, Chu CM, Lin SM, Wang CJ, et al. Diagnostic laparoscopy in ascites of unknown origin: Chang Gung Memorial Hospital 20-year experience. Chang Gung Med J. 2008; 31(4): 378-83.
 
51 - Hauswald H (2008)
Hauswald H, Lindel K, Rochet N, Debus J, Harms W. Surgery with complete resection improves survival in radiooncologically treated patients with cervical lymph node metastases from cancer of unknown primary. Strahlenther Onkol. 2008; 184(3): 150-6.
 
52 - Hawksworth J (2004)
Hawksworth J, Geisinger K, Zagoria R, Kavanagh P, Howerton R, Levine EA, et al. Surgical and ablative treatment for metastatic adenocarcinoma to the liver from unknown primary tumor. Am Surg. 2004; 70(6): 512-7.
 
53 - Hayashi T (2010)
Hayashi T, Muto M, Hayashi R, Minashi K, Yano T, Kishimoto S, et al. Usefulness of narrow-band imaging for detecting the primary tumor site in patients with primary unknown cervical lymph node metastasis. Jpn J Clin Oncol. 2010; 40(6): 537-41.
 
54 - Hewitt MJ (2007)
Hewitt MJ, Anderson K, Hall GD, Weston M, Hutson R, Wilkinson N, et al. Women with peritoneal carcinomatosis of unknown origin: Efficacy of image-guided biopsy to determine site-specific diagnosis. BJOG. 2007; 114(1): 46-50.
 
55 - Hong AM (2010)
Hong AM, Dobbins TA, Lee CS, Jones D, Harnett GB, Armstrong BK, et al. Human papillomavirus predicts outcome in oropharyngeal cancer in patients treated primarily with surgery or radiation therapy. Br J Cancer. 2010; 103(10): 1510-7.
 
56 - Hoving C (2010)
Hoving C, Visser A, Mullen PD, van den Borne B. A history of patient education by health professionals in Europe and North America: from authority to shared decision making education. Patient Educ Couns. 2010; 78(3): 275-81.
 
57 - Huebner G (2009)
Huebner G, Link H, Kohne CH, Stahl M, Kretzschmar A, Steinbach S, et al. Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial. Br J Cancer. 2009; 100(1): 44-9.
 
58 - Idikio HA (2009)
Idikio HA. Immunohistochemistry in diagnostic surgical pathology: contributions of protein life-cycle, use of evidence-based methods and data normalization on interpretation of immunohistochemical stains. Int J Clin Exp Pathol. 2009; 3(2): 169-76.
 
59 - Iizuka Y (2009)
Iizuka Y, Iizuka H, Tsutsumi S, Nakagawa Y, Nakajima T, Sorimachi Y, et al. Diagnosis of a previously unidentified primary site in patients with spinal metastasis: diagnostic usefulness of laboratory analysis, CT scanning and CT-guided biopsy. Eur Spine J. 2009; 18(10): 1431-5.
 
60 - Jannapureddy S (2010)
Jannapureddy S, Cohen C, Lau S, Beitler JJ, Siddiqui MT. Assessing for primary oropharyngeal or nasopharyngeal squamous cell carcinoma from fine needle aspiration of cervical lymph node metastases. Diagn Cytopathol. 2010; 38(11): 795-800.
 
61 - Johansen J (2008)
Johansen J, Buus S, Loft A, Keiding S, Overgaard M, Hansen HS, et al. Prospective study of 18FDG-PET in the detection and management of patients with lymph node metastases to the neck from an unknown primary tumor. Results from the DAHANCA-13 study. Head Neck. 2008; 30(4): 471-8.
 
62 - Joshi U (2004)
Joshi U, van der Hoeven JJ, Comans EF, Herder GJ, Teule GJ, Hoekstra OS. In search of an unknown primary tumour presenting with extracervical metastases: the diagnostic performance of FDG-PET. Br J Radiol. 2004; 77(924): 1000-6.
 
63 - Jungehulsing M (2000)
Jungehulsing M, Scheidhauer K, Damm M, Pietrzyk U, Eckel H, Schicha H, et al. 2[F]-fluoro-2-deoxy-D-glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation. Otolaryngol Head Neck Surg. 2000; 123(3): 294-301.
 
64 - Kaya AO (2008)
Kaya AO, Coskun U, Unlu M, Akdemir UO, Ozdemir NY, Zengin N, et al. Whole body 18F-FDG PET/CT imaging in the detection of primary tumours in patients with a metastatic carcinoma of unknown origin. Asian Pac J Cancer Prev. 2008; 9(4): 683-6.
 
65 - Koch WM (2001)
Koch WM, Bhatti N, Williams MF, Eisele DW. Oncologic rationale for bilateral tonsillectomy in head and neck squamous cell carcinoma of unknown primary source. Otolaryngol Head Neck Surg. 2001; 124(3): 331-3.
 
66 - Kodaira M (2010)
Kodaira M, Takahashi S, Yamada S, Ueda K, Mishima Y, Takeuchi K, et al. Bone metastasis and poor performance status are prognostic factors for survival of carcinoma of unknown primary site in patients treated with systematic chemotherapy. Ann Oncol. 2010; 21(6): 1163-7.
 
67 - Koivunen P (2002)
Koivunen P, Laranne J, Virtaniemi J, Back L, Makitie A, Pulkkinen J, et al. Cervical metastasis of unknown origin: a series of 72 patients. Acta Otolaryngol. 2002; 122(5): 569-74.
 
68 - Kolesnikov (2005)
Kolesnikov-Gauthier H, Levy E, Merlet P, Kirova J, Syrota A, Carpentier P, et al. FDG PET in patients with cancer of an unknown primary. Nucl Med Commun. 2005; 26(12): 1059-66.
 
69 - Kothari P (2008)
Kothari P, Randhawa PS, Farrell R. Role of tonsillectomy in the search for a squamous cell carcinoma from an unknown primary in the head and neck. Br J Oral Maxillofac Surg. 2008; 46(4): 283-7.
 
70 - Kramer A (2009)
Kramer A, Gattenlohner S, Neben K. [CUP syndrome: molecular pathogenesis and biology]. Pathologe. 2009; 30(2): 117-24.
 
71 - Kwee TC (2010)
Kwee TC, Basu S, Cheng G, Alavi A. FDG PET/CT in carcinoma of unknown primary. Eur J Nucl Med Mol Imaging. 2010; 37(3): 635-44.
 
72 - Kwee TC (2009)
Kwee TC, Kwee RM. Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. Eur Radiol. 2009; 19(3): 731-44.
 
73 - Lau HY (2011)
Lau HY, Brar S, Klimowicz AC, Petrillo SK, Hao D, Brockton NT, et al. Prognostic significance of p16 in locally advanced squamous cell carcinoma of the head and neck treated with concurrent cisplatin and radiotherapy. Head Neck. 2011; 33(2): 251-6.
 
74 - Laveau F (2001)
Laveau F, Picot MC, Dereure O, Guilhou JJ, Guillot B. [Metastatic melanoma of unknown primary site]. Ann Dermatol Venereol. 2001; 128(8-9): 893-8.
 
75 - Lazaridis G (2008)
Lazaridis G, Pentheroudakis G, Fountzilas G, Pavlidis N. Liver metastases from cancer of unknown primary (CUPL): a retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature. Cancer Treat Rev. 2008; 34(8): 693-700.
 
76 - Lee CC (2009)
Lee CC, Faries MB, Wanek LA, Morton DL. Improved survival for stage IV melanoma from an unknown primary site. J Clin Oncol. 2009; 27(21): 3489-95.
 
77 - Liao YT (2010)
Liao YT, Wu MH, Wang MY, Lee PC, Yang CY, Lin MT, et al. Gasless laparoscopy-assisted surgery for intraabdominal/retroperitoneal tumor of unknown origin: a bridge between total laparoscopic surgery and conventional open surgery. J Laparoendosc Adv Surg Tech A. 2010; 20(10): 825-30.
 
78 - Ligey A (2009)
Ligey A, Gentil J, Crehange G, Montbarbon X, Pommier P, Peignaux K, et al. Impact of target volumes and radiation technique on loco-regional control and survival for patients with unilateral cervical lymph node metastases from an unknown primary. Radiother Oncol. 2009; 93(3): 483-7.
 
79 - Lortholary A (2001)
Lortholary A, Abadie-Lacourtoisie S, Guerin O, Mege M, Rauglaudre GD, Gamelin E. [Cancers of unknown origin: 311 cases]. Bull Cancer. 2001; 88(6): 619-27.
 
80 - Maesawa S (2000)
Maesawa S, Kondziolka D, Thompson TP, Flickinger JC, Dade L. Brain metastases in patients with no known primary tumor. Cancer. 2000; 89(5): 1095-101.
 
81 - McKeon A (2010)
McKeon A, Apiwattanakul M, Lachance DH, Lennon VA, Mandrekar JN, Boeve BF, et al. Positron emission tomography-computed tomography in paraneoplastic neurologic disorders: systematic analysis and review. Arch Neurol. 2010; 67(3): 322-9.
 
82 - McMahon J (2000)
McMahon J, Hruby G, O'Brien CJ, McNeil EB, Bagia JS, Clifford AR, et al. Neck dissection and ipsilateral radiotherapy in the management of cervical metastatic carcinoma from an unknown primary. Aust N Z J Surg. 2000; 70(4): 263-8.
 
83 - McMahon K (2005)
McMahon K, Medoro L, Kennedy D. Breast magnetic resonance imaging: an essential role in malignant axillary lymphadenopathy of unknown origin. Australas Radiol. 2005; 49(5): 382-9.
 
84 - Miller FR (2005)
Miller FR, Hussey D, Beeram M, Eng T, McGuff HS, Otto RA. Positron emission tomography in the management of unknown primary head and neck carcinoma. Arch Otolaryngol Head Neck Surg. 2005; 131(7): 626-9.
 
85 - Miller FR (2008)
Miller FR, Karnad AB, Eng T, Hussey DH, Stan McGuff H, Otto RA. Management of the unknown primary carcinoma: long-term follow-up on a negative PET scan and negative panendoscopy. Head Neck. 2008; 30(1): 28-34.
 
86 - Mistry RC (2008)
Mistry RC, Qureshi SS, Talole SD, Deshmukh S. Cervical lymph node metastases of squamous cell carcinoma from an unknown primary: outcomes and patterns of failure. Indian J Cancer. 2008; 45(2): 54-8.
 
87 - Miwa K (2009)
Miwa K, Fujioka S, Adachi Y, Haruki T, Taniguchi Y, Nakamura H. Mediastinal lymph node carcinoma of an unknown primary site: clinicopathological examination. Gen Thorac Cardiovasc Surg. 2009; 57(5): 239-43.
 
88 - Moll R (2009)
Moll R. [The initial CUP situation and CUP syndrome: pathological diagnostics]. Pathologe. 2009; 30 Suppl 2: 161-7.
 
89 - Moller AK (2010)
Moller AK, Pedersen KD, Abildgaard J, Petersen BL, Daugaard G. Capecitabine and oxaliplatin as second-line treatment in patients with carcinoma of unknown primary site. Acta Oncol. 2010; 49(4): 431-5.
 
90 - Moller AK (2010)
Moller AK, Pedersen KD, Gothelf A, Daugaard G. Paclitaxel, cisplatin and gemcitabine in treatment of carcinomas of unknown primary site, a phase II study. Acta Oncol. 2010; 49(4): 423-30.
 
91 - Monzon FA (2010)
Monzon FA, Koen TJ. Diagnosis of metastatic neoplasms: molecular approaches for identification of tissue of origin. Arch Pathol Lab Med. 2010; 134(2): 216-24.
 
92 - Morawietz L (2009)
Morawietz L, Floore A, Stork-Sloots L, Folprecht G, Buettner R, Rieger A, et al. [Comparing immunohistochemical diagnosis of cancer of unknown primary with gene expression-based tumor classification]. Pathologe. 2009; 30 Suppl 2: 168-72.
 
93 - Mukai H (2010)
Mukai H, Katsumata N, Ando M, Watanabe T. Safety and efficacy of a combination of docetaxel and cisplatin in patients with unknown primary cancer. Am J Clin Oncol. 2010; 33(1): 32-5.
 
94 - Mylona S (2009)
Mylona S, Stroumpouli E, Pomoni M, Galani P, Ntai S, Thanos L. Radiofrequency ablation of liver metastases from cancer of unknown primary site. Diagn Interv Radiol. 2009; 15(4): 297-302.
 
95 - Nieder C (2002)
Nieder C, Ang KK. Cervical lymph node metastases from occult squamous cell carcinoma. Curr Treat Options Oncol. 2002; 3(1): 33-40.
 
96 - Nieder C (2001)
Nieder C, Gregoire V, Ang KK. Cervical lymph node metastases from occult squamous cell carcinoma: cut down a tree to get an apple? Int J Radiat Oncol Biol Phys. 2001; 50(3): 727-33.
 
97 - Niranjan A (2010)
Niranjan A, Kano H, Khan A, Kim IY, Kondziolka D, Flickinger JC, et al. Radiosurgery for brain metastases from unknown primary cancers. Int J Radiat Oncol Biol Phys. 2010; 77(5): 1457-62.
 
98 - Oien KA (2009)
Oien KA. Pathologic evaluation of unknown primary cancer. Semin Oncol. 2009; 36(1): 8-37.
 
99 - Padovani D (2009)
Padovani D, Aimoni C, Zucchetta P, Paluzzi A, Pastore A. 18-FDG PET in the diagnosis of laterocervical metastases from occult carcinoma. Eur Arch Otorhinolaryngol. 2009; 266(2): 267-71.
 
100 - Park JM (2010)
Park JM, Jung CK, Choi YJ, Lee KY, Kang JH, Kim MS, et al. The use of an immunohistochemical diagnostic panel to determine the primary site of cervical lymph node metastases of occult squamous cell carcinoma. Hum Pathol. 2010; 41(3): 431-7.
 
101 - Paul SA (2007)
Paul SA, Stoeckli SJ, von Schulthess GK, Goerres GW. FDG PET and PET/CT for the detection of the primary tumour in patients with cervical non-squamous cell carcinoma metastasis of an unknown primary. Eur Arch Otorhinolaryngol. 2007; 264(2): 189-95.
 
102 - Pavlidis N (2003)
Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer. 2003; 39(14): 1990-2005.
 
103 - Pavlidis N (2009)
Pavlidis N, Fizazi K. Carcinoma of unknown primary (CUP). Crit Rev Oncol Hematol. 2009; 69(3): 271-8.
 
104 - Pavlidis N (2009)
Pavlidis N, Pentheroudakis G, Plataniotis G. Cervical lymph node metastases of squamous cell carcinoma from an unknown primary site: a favourable prognosis subset of patients with CUP. Clin Transl Oncol. 2009; 11(6): 340-8.
 
105 - Pelosi E (2006)
Pelosi E, Pennone M, Deandreis D, Douroukas A, Mancini M, Bisi G. Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site. Q J Nucl Med Mol Imaging. 2006; 50(1): 15-22.
 
106 - Penel N (2009)
Penel N, Negrier S, Ray-Coquard I, Ferte C, Devos P, Hollebecque A, et al. Development and validation of a bedside score to predict early death in cancer of unknown primary patients. PLoS One. 2009; 4(8): e6483.
 
107 - Pentheroudakis G (2007)
Pentheroudakis G, Golfinopoulos V, Pavlidis N. Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer. 2007; 43(14): 2026-36.
 
108 - Pentheroudakis G (2009)
Pentheroudakis G, Greco FA, Pavlidis N. Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: a systematic literature review. Cancer Treat Rev. 2009; 35(3): 221-7.
 
109 - Pentheroudakis G (2010)
Pentheroudakis G, Lazaridis G, Pavlidis N. Axillary nodal metastases from carcinoma of unknown primary (CUPAx): a systematic review of published evidence. Breast Cancer Res Treat. 2010; 119(1): 1-11.
 
110 - Pentheroudakis G (2010)
Pentheroudakis G, Pavlidis N. Serous papillary peritoneal carcinoma: unknown primary tumour, ovarian cancer counterpart or a distinct entity? A systematic review. Crit Rev Oncol Hematol. 2010; 75(1): 27-42.
 
111 - Pentz RD (2002)
Pentz RD, Lenzi R, Holmes F, Khan MM, Verschraegen C. Discussion of the do-not-resuscitate order: a pilot study of perceptions of patients with refractory cancer. Support Care Cancer. 2002; 10(8): 573-8.
 
112 - Perie S (2000)
Perie S, Talbot JN, Monceaux G, Grahek D, Kerrou K, Montravers F, et al. Use of a coincidence gamma camera to detect primary tumor with 18fluoro-2-deoxy-glucose in cervical lymph node metastases from an unknown origin. Ann Otol Rhinol Laryngol. 2000; 109(8 Pt 1): 755-60.
 
113 - Peter S (2009)
Peter S, Eltoum I, Eloubeidi MA. EUS-guided FNA of peritoneal carcinomatosis in patients with unknown primary malignancy. Gastrointest Endosc. 2009; 70(6): 1266-70.
 
114 - Pimiento JM (2007)
Pimiento JM, Teso D, Malkan A, Dudrick SJ, Palesty JA. Cancer of unknown primary origin: a decade of experience in a community-based hospital. Am J Surg. 2007; 194(6): 833-7; discussion 7-8.
 
115 - Ponce Lorenzo J (2007)
Ponce Lorenzo J, Segura Huerta A, Diaz Beveridge R, Gimenez Ortiz A, Aparisi Aparisi F, Fleitas Kanonnikoff T, et al. Carcinoma of unknown primary site: development in a single institution of a prognostic model based on clinical and serum variables. Clin Transl Oncol. 2007; 9(7): 452-8.
 
116 - Pool SE (2010)
Pool SE, Krenning EP, Koning GA, van Eijck CH, Teunissen JJ, Kam B, et al. Preclinical and clinical studies of peptide receptor radionuclide therapy. Semin Nucl Med. 2010; 40(3): 209-18.
 
117 - Prasad V (2010)
Prasad V, Ambrosini V, Hommann M, Hoersch D, Fanti S, Baum RP. Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imaging. 2010; 37(1): 67-77.
 
118 - Quon G (2009)
Quon G, Morris Q. ISOLATE: a computational strategy for identifying the primary origin of cancers using high-throughput sequencing. Bioinformatics. 2009; 25(21): 2882-9.
 
119 - Rabban JT (2009)
Rabban JT, Krasik E, Chen LM, Powell CB, Crawford B, Zaloudek CJ. Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingo-oophorectomies from women with BRCA mutations: implications for defining an optimal specimen dissection protocol. Am J Surg Pathol. 2009; 33(12): 1878-85.
 
120 - Rades D (2001)
Rades D, Kuhnel G, Wildfang I, Borner AR, Knapp W, Karstens JH. [The value of positron emission tomography (PET) in the treatment of patients with cancer of unknown primary (CUP)]. Strahlenther Onkol. 2001; 177(10): 525-9.
 
121 - Randen M (1960)
Randen M, Rutqvist LE, Johansson H. Cancer patients without a known primary: incidence and survival trends in Sweden 1960-2007. Acta Oncol. 2009; 48(6): 915-20.
 
122 - Regelink G (2002)
Regelink G, Brouwer J, de Bree R, Pruim J, van der Laan BF, Vaalburg W, et al. Detection of unknown primary tumours and distant metastases in patients with cervical metastases: value of FDG-PET versus conventional modalities. Eur J Nucl Med Mol Imaging. 2002; 29(8): 1024-30.
 
123 - Riquet M (2003)
Riquet M, Badoual C, le Pimpec BF, Dujon A, Danel C. Metastatic thoracic lymph node carcinoma with unknown primary site. Ann Thorac Surg. 2003; 75(1): 244-9.
 
124 - Rodary C (2004)
Rodary C, Pezet-Langevin V, Garcia-Acosta S, Lesimple T, Lortholary A, Kaminsky MC, et al. Patient preference for either the EORTC QLQ-C30 or the FACIT Quality Of Life (QOL) measures: a study performed in patients suffering from carcinoma of an unknown primary site (CUP). Eur J Cancer. 2004; 40(4): 521-8.
 
125 - Rodel RM (2009)
Rodel RM, Matthias C, Blomeyer BD, Wolff HA, Jung K, Christiansen H. Impact of distant metastasis in patients with cervical lymph node metastases from cancer of an unknown primary site. Ann Otol Rhinol Laryngol. 2009; 118(9): 662-9.
 
126 - Roh JL (2009)
Roh JL, Kim JS, Lee JH, Cho KJ, Choi SH, Nam SY, et al. Utility of combined (18)F-fluorodeoxyglucose-positron emission tomography and computed tomography in patients with cervical metastases from unknown primary tumors. Oral Oncol. 2009; 45(3): 218-24.
 
127 - Ruda R (2001)
Ruda R, Borgognone M, Benech F, Vasario E, Soffietti R. Brain metastases from unknown primary tumour: a prospective study. J Neurol. 2001; 248(5): 394-8.
 
128 - Rusthoven KE (2004)
Rusthoven KE, Koshy M, Paulino AC. The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor. Cancer. 2004; 101(11): 2641-9.
 
129 - Rutkowski P (2010)
Rutkowski P, Nowecki ZI, Dziewirski W, Zdzienicki M, Pienkowski A, Salamacha M, et al. Melanoma without a detectable primary site with metastases to lymph nodes. Dermatol Surg. 2010; 36(6): 868-76.
 
130 - Sakai A (2010)
Sakai A, Okami K, Ebisumoto K, Sugimoto R, Maki D, Iida M. New techniques to detect unknown primaries in cervical lymph node metastasis. Laryngoscope. 2010; 120(9): 1779-83.
 
131 - Schuette K (2009)
Schuette K, Folprecht G, Kretzschmar A, Link H, Koehne CH, Gruenwald V, et al. Phase II trial of capecitabine and oxaliplatin in patients with adeno- and undifferentiated carcinoma of unknown primary. Onkologie. 2009; 32(4): 162-6.
 
132 - Schwab FD (2010)
Schwab FD, Burger H, Isenschmid M, Kuhn A, Mueller MD, Gunthert AR. Suspicious axillary lymph nodes in patients with unremarkable imaging of the breast. Eur J Obstet Gynecol Reprod Biol. 2010; 150(1): 88-91.
 
133 - Scott CL (2005)
Scott CL, Kudaba I, Stewart JM, Hicks RJ, Rischin D. The utility of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in the investigation of patients with disseminated carcinoma of unknown primary origin. Mol Imaging Biol. 2005; 7(3): 236-43.
 
134 - Sendler A (2008)
Sendler A, Strumberg D, Tannapfel A. [Carcinoma of unknown primary site (CUP syndrome)]. Chirurg. 2008; 79(7): 689-95; quiz 96.
 
135 - Shaw PH (2007)
Shaw PH, Adams R, Jordan C, Crosby TD. A clinical review of the investigation and management of carcinoma of unknown primary in a single cancer network. Clin Oncol (R Coll Radiol). 2007; 19(1): 87-95.
 
136 - Sher DJ (2011)
Sher DJ, Balboni TA, Haddad RI, Norris CM, Jr., Posner MR, Wirth LJ, et al. Efficacy and toxicity of chemoradiotherapy using intensity-modulated radiotherapy for unknown primary of head and neck. Int J Radiat Oncol Biol Phys. 2011; 80(5): 1405-11.
 
137 - Shoushtari A (2011)
Shoushtari A, Saylor D, Kerr KL, Sheng K, Thomas C, Jameson M, et al. Outcomes of Patients with Head-and-Neck Cancer of Unknown Primary Origin Treated with Intensity-Modulated Radiotherapy. Int J Radiat Oncol Biol Phys. 2011.
 
138 - Sorgho-Lougue LC (2006)
Sorgho-Lougue LC, Luciani A, Kobeiter H, Zelek L, Malhaire C, Deux JF, et al. Adenocarcinomas of unknown primary (ACUP) of the mediastinum mimicking lymphoma: CT findings at diagnosis and follow-up. Eur J Radiol. 2006; 59(1): 42-8.
 
139 - Srirajaskanthan R (2010)
Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J Nucl Med. 2010; 51(6): 875-82.
 
140 - Strojan Flezar M (2009)
Strojan Flezar M, Srebotnik Kirbis I. Identification of carcinoma origin by thyroid transcription factor-1 immunostaining of fine needle aspirates of metastases. Cytopathology. 2009; 20(3): 176-82.
 
141 - Strojan P FA (2011)
Strojan P FA, Langendijk JA, Corry J, Woolgar JA, Rinaldo A, et al. Contemporary management of lymph node metastases from an unknown primary to the neck: II A review of therapeutic options. Head & Neck. 2011: DOI 10.1002/hed.21899.
 
142 - Subramaniam RM (2010)
Subramaniam RM, Truong M, Peller P, Sakai O, Mercier G. Fluorodeoxyglucose-positron-emission tomography imaging of head and neck squamous cell cancer. AJNR Am J Neuroradiol. 2010; 31(4): 598-604.
 
143 - Symons J (2008)
Symons J. Supporting patients with cancer of unknown primary. Nurs Times. 2008; 104(14): 23-4.
 
144 - Teo PM (2002)
Teo PM, Chan AT. Treatment strategy and clinical experience. Semin Cancer Biol. 2002; 12(6): 497-504.
 
145 - Thom I (2009)
Thom I, Rogers C, Andritzky B, Witzel I, Schuch G, Hossfeld DK, et al. Single-center management of 136 patients with cancer of unknown primary site (CUP syndrome) over a period of 10 years. Onkologie. 2009; 32(12): 741-6.
 
146 - Tong CC (2002)
Tong CC, Luk MY, Chow SM, Ngan KC, Lau WH. Cervical nodal metastases from occult primary: undifferentiated carcinoma versus squamous cell carcinoma. Head Neck. 2002; 24(4): 361-9.
 
147 - Tuinman MA (2008)
Tuinman MA, Gazendam-Donofrio SM, Hoekstra-Weebers JE. Screening and referral for psychosocial distress in oncologic practice: use of the Distress Thermometer. Cancer. 2008; 113(4): 870-8.
 
148 - van de Wouw AJ (1984)
van de Wouw AJ, Janssen-Heijnen ML, Coebergh JW, Hillen HF. Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992. Eur J Cancer. 2002; 38(3): 409-13.
 
149 - van Laar RK (2009)
van Laar RK, Ma XJ, de Jong D, Wehkamp D, Floore AN, Warmoes MO, et al. Implementation of a novel microarray-based diagnostic test for cancer of unknown primary. Int J Cancer. 2009; 125(6): 1390-7.
 
150 - van Veen SA (2001)
van Veen SA, Balm AJ, Valdes Olmos RA, Hoefnagel CA, Hilgers FJ, Tan IB, et al. Occult primary tumors of the head and neck: accuracy of thallium 201 single-photon emission computed tomography and computed tomography and/or magnetic resonance imaging. Arch Otolaryngol Head Neck Surg. 2001; 127(4): 406-11.
 
151 - Varadhachary GR (2009)
Varadhachary GR, Greco FA. Overview of patient management and future directions in unknown primary carcinoma. Semin Oncol. 2009; 36(1): 75-80.
 
152 - Varadhachary GR (2008)
Varadhachary GR, Raber MN, Matamoros A, Abbruzzese JL. Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions. Lancet Oncol. 2008; 9(6): 596-9.
 
153 - Visser A (2010)
Visser A, Wysmans M. Improving patient education by an in-service communication training for health care providers at a cancer ward: communication climate, patient satisfaction and the need of lasting implementation. Patient Educ Couns. 2010; 78(3): 402-8.
 
154 - Vollmer RT (2009)
Vollmer RT. Differential diagnosis in immunohistochemistry with Bayes theorem. Am J Clin Pathol. 2009; 131(5): 723-30.
 
155 - Wallace A (2011)
Wallace A, Richards GM, Harari PM, Kirwan JM, Morris CG, Katakam H, et al. Head and neck squamous cell carcinoma from an unknown primary site. Am J Otolaryngol. 2011; 32(4): 286-90.
 
156 - Waltonen JD (2009)
Waltonen JD, Ozer E, Hall NC, Schuller DE, Agrawal A. Metastatic carcinoma of the neck of unknown primary origin: evolution and efficacy of the modern workup. Arch Otolaryngol Head Neck Surg. 2009; 135(10): 1024-9.
 
157 - Waltonen JD (2009)
Waltonen JD, Ozer E, Schuller DE, Agrawal A. Tonsillectomy vs. deep tonsil biopsies in detecting occult tonsil tumors. Laryngoscope. 2009; 119(1): 102-6.
 
158 - Wang SC (2010)
Wang SC, Parekh JR, Zuraek MB, Venook AP, Bergsland EK, Warren RS, et al. Identification of unknown primary tumors in patients with neuroendocrine liver metastases. Arch Surg. 2010; 145(3): 276-80.
 
159 - Wartski M (2007)
Wartski M, Le Stanc E, Gontier E, Vilain D, Banal A, Tainturier C, et al. In search of an unknown primary tumour presenting with cervical metastases: performance of hybrid FDG-PET-CT. Nucl Med Commun. 2007; 28(5): 365-71.
 
160 - Weber A (2001)
Weber A, Schmoz S, Bootz F. CUP (carcinoma of unknown primary) syndrome in head and neck: clinic, diagnostic, and therapy. Onkologie. 2001; 24(1): 38-43.
 
161 - Wei S (2009)
Wei S, Said-Al-Naief N, Hameed O. Estrogen and progesterone receptor expression is not always specific for mammary and gynecologic carcinomas: a tissue microarray and pooled literature review study. Appl Immunohistochem Mol Morphol. 2009; 17(5): 393-402.
 
162 - Wong WL (2003)
Wong WL, Saunders M. The impact of FDG PET on the management of occult primary head and neck tumours. Clin Oncol (R Coll Radiol). 2003; 15(8): 461-6.
 
163 - Yakushiji S (2006)
Yakushiji S, Ando M, Yonemori K, Kohno T, Shimizu C, Katsumata N, et al. Cancer of unknown primary site: review of consecutive cases at the National Cancer Center Hospital of Japan. Int J Clin Oncol. 2006; 11(6): 421-5.
 
164 - Yanagawa T (2010)
Yanagawa T, Shinozaki T, Iizuka Y, Takagishi K, Watanabe H. Role of 2-deoxy-2-[F-18] fluoro-D-glucose positron emission tomography in the management of bone and soft-tissue metastases. J Bone Joint Surg Br. 2010; 92(3): 419-23.
 
165 - Yapar Z (2010)
Yapar Z, Kibar M, Yapar AF, Paydas S, Reyhan M, Kara O, et al. The value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in carcinoma of an unknown primary: diagnosis and follow-up. Nucl Med Commun. 2010; 31(1): 59-66.
 
166 - Yonemori K (2009)
Yonemori K, Ando M, Yunokawa M, Hirata T, Kouno T, Shimizu C, et al. Irinotecan plus carboplatin for patients with carcinoma of unknown primary site. Br J Cancer. 2009; 100(1): 50-5.
 
167 - Yoon YJ (2007)
Yoon YJ, Ahn SH, Park JY, Chon CY, Kim do Y, Park YN, et al. What is the role of diagnostic laparoscopy in a gastroenterology unit? J Gastroenterol. 2007; 42(11): 881-6.
 
168 - Zemskova MS (2010)
Zemskova MS, Gundabolu B, Sinaii N, Chen CC, Carrasquillo JA, Whatley M, et al. Utility of various functional and anatomic imaging modalities for detection of ectopic adrenocorticotropin-secreting tumors. J Clin Endocrinol Metab. 2010; 95(3): 1207-19.
 
169 - Zhang MQ (2008)
Zhang MQ, El-Mofty SK, Davila RM. Detection of human papillomavirus-related squamous cell carcinoma cytologically and by in situ hybridization in fine-needle aspiration biopsies of cervical metastasis: a tool for identifying the site of an occult head and neck primary. Cancer. 2008; 114(2): 118-23.
 
170 - Zuur CL (2002)
Zuur CL, van Velthuysen ML, Schornagel JH, Hilgers FJ, Balm AJ. Diagnosis and treatment of isolated neck metastases of adenocarcinomas. Eur J Surg Oncol. 2002; 28(2): 147-52.